Administration costs of intravenous biologic drugs for rheumatoid arthritis
نویسندگان
چکیده
منابع مشابه
Administration costs of intravenous biologic drugs for rheumatoid arthritis
BACKGROUND Cost-effectiveness studies explicitly reporting infusion times, drug-specific administration costs for infusions or real-payer intravenous drug cost are few in number. Yet, administration costs for infusions are needed in the health economic evaluations assessing intravenously-administered drugs. OBJECTIVES To estimate the drug-specific administration and total cost of biologic int...
متن کاملSafety of conventional drugs and biologic agents for Rheumatoid Arthritis.
While initial researches documented that Rheumatoid Arthritis (RA) patients who took biologic agents had decreased symptoms with those receiving traditional treatment, safety of the drugs remains a concern. The authors in this paper review the safety of the RA new therapeutic approach utilizing biological agents and compare it with the safety of conventional disease-modifying anti-rheumatic dru...
متن کاملBone Effects of Biologic Drugs in Rheumatoid Arthritis
Biologic agents used in the treatment of rheumatoid arthritis (RA) are able to reduce both disease activity and radiographic progression of joint disease. These drugs are directed against several proinflammatory cytokines (TNF α , IL-6, and IL-1) which are involved both in the pathogenesis of chronic inflammation and progression of joint structural damage and in systemic and local bone loss typ...
متن کاملBiologic Treatment in Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a common, chronic, inflammatory disease. It affects around 1% of the adult population in all age groups, although the incidence peaks during the fifth decade of life. The aetiology of RA is unknown, but it is considered to be autoimmune in nature. Inflammation in the synovial tissues of the joints is the hallmark of RA, causing pain, stiffness, loss of function and ...
متن کاملIndirect costs of rheumatoid arthritis
It is estimated that in Poland about 400,000 persons in general suffer from inflammatory joint diseases, including rheumatoid arthritis (RA). Epidemiological surveys documenting the frequency and disturbance of musculoskeletal disorders in the Polish population are few in number. Most of the estimations are based on epidemiological data from other countries (prevalence of 0.5-1%). According to ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: SpringerPlus
سال: 2013
ISSN: 2193-1801
DOI: 10.1186/2193-1801-2-531